[MCQs] Antiplatelet, Anticoagulant, and Fibrinolytic Drugs – Part 1

I. Start the exam by click the “Start” button

See all quizzes of  the Antiplatelet, Anticoagulant, and Fibrinolytic Drugs  at here:

Antiplatelet, Anticoagulant, and Fibrinolytic Drugs – Part 1 | Antiplatelet, Anticoagulant, and Fibrinolytic Drugs – Part 2

Antiplatelet, Anticoagulant, and Fibrinolytic Drugs – Part 3 | Antiplatelet, Anticoagulant, and Fibrinolytic Drugs – Part 4

II. Preview all questions below:

1. Circulating platelets are maintained in an inactive state by ?
A. Nitric oxide (NO)
B. Prostacyclin
C. CD39

D. All of the above

2.  Thromboxane A2 (TxA2) plays a role in ?

A. Activating platelets
B. Constricting blood vessels
C. Promoting atherogenesis by inducing proliferation of vascular smooth muscle cells
D. All of the above

3. Which of the following statements is false ?
A. NSAIDs (ibuprofen/diclofenac) are reversible inhibitors of COX
B. In mature human platelets, COX-2 are absent
C. Thromboxane A2 can be produced in monocytes and macrophages
D. None of the above

4.  Which of the following drugs is used in arterial disease management ?
A. That inhibit platelet activation & aggregation
B. That inhibit thrombin generation
C. That inhibit fibrin generation
D. All of the above

5. At what dose, aspirin also inhibits COX-2 ?
A. ~ 325 mg / day
B. ~ 500 mg / day
C. ~ 750 mg / day
D. ~ 1000 mg / day

5.  Aspirin can produce antithrombotic effect at a dose of ?
A. 20 mg/day
B. 30 mg/day
C. 40 mg/day
D. 50 mg/day

6.  The major thrombin receptor on human platelets is ?
A. Glycoprotein (GP) IIb/IIIa
B. Integrin 21
C. Protease-activated receptor-1 (PAR-1)
D. GPIb-IX-V

7.  Compared with placebo, aspirin produces a reduction in the risk of cardiovascular death, MI, or stroke by ?
A. 5 %
B. 15 %
C. 25 %
D. 35 %

7.  For most indications, recommended daily dose of aspirin is ?
A. 40 – 75 mg
B. 75 – 100 mg
C. 100 – 150 mg
D. 150 – 300 mg

8.  Ticlopidine, clopidogrel, and prasugrel irreversibly block which of the following ?
A. P2X12
B. P2Y12
C. P2X21
D. P2Y21

9.  Which of the following is a prodrug ?
A. Ticlopidine
B. Clopidogrel
C. Prasugrel
D. All of the above

10.  Compared with aspirin, clopidogrel produces a reduction in the risk of cardiovascular death, MI, or stroke by ?
A. 2.5 %
B. 8.7 %
C. 13.5 %
D. 18.2 %

11. Which of the following drugs is known to produce thrombotic thrombocytopenic purpura (TTP) ?
A. Ticlopidine
B. Dipyridamole
C. Tirofiban
D. Aspirin

12.  Which of the following represents the final common pathway of platelet activation ?
A. Cyclooxygenase (COX)
B. Adenosine diphosphate (ADP) receptors
C. Gp Ib
D. Gp IIb/IIIa

13. Which drug was studied in the ‘CAPRIE trial’ ?
A. Aspirin
B. Ticlopidine and clopidogrel
C. Clopidogrel
D. All of the above

14. The main metabolite of Clopidogrel is ?
A. SR 25334
B. SR 26334
C. SR 27334
D. SR 28334

15.  Subjects with which of the following allele exhibit decrease dresponsiveness to clopidogrel ?
A. CYP2C17*2
B. CYP2C18*2
C. CYP2C19*2
D. CYP2C20*2

16.  Which of the following is a platelet membrane glycoprotein receptor ?
A. Glycoprotein Ia-IIa
B. Glycoprotein Ib-V-IX
C. Glycoprotein IIb-IIIa
D. All of the above

17.  Which of the following is a GPIIb/IIIA receptor antagonist ?
A. Abciximab
B. Eptifibatide
C. Tirofiban
D. All of the above

18.  Which of the following is false about GPIIb/IIIa adhesion receptors ?
A. Found on surface of platelets & megakaryocytes
B. About 80,000 per platelet
C. GPIIb/IIIa is inactive on resting platelets
D. None of the above

19.  Once activated, GPIIb/IIIa binds which of the following ?
A. Thrombin
B. RBC
C. Fibrinogen
D. WBC

20.  Deficiency of which of the following results in Glanzmann’s thrombasthenia ?
A. Glycoprotein IIb-IIIa
B. Glycoprotein Ia-IIa
C. Glycoprotein Ib-V-IX
D. All of the above

21.  Which of the following target the GPIIb / IIIa receptor ?
A. Abciximab
B. Eptifibatide
C. Tirofiban
D. All of the above

22.  Which of the following is a Fab fragment of a humanized murine monoclonal antibody ?
A. Abciximab
B. Eptifibatide
C. Tirofiban
D. All of the above

23.  Which of the following GPIIb/IIIa antagonists are given as an IV bolus followed by an infusion ?
A. Abciximab
B. Eptifibatide
C. Tirofiban
D. All of the above